The science behind aging and how to slow it has never been more compelling, and OneSkin is at the forefront of this rapidly emerging field. The pioneering skin longevity brand, known for leveraging biotech to target the underlying mechanisms of skin aging, has announced a $20 million Series. An investment from growth equity firm Prelude Growth Partners.
The funding round, completed last month, isn’t just about expanding resources; it’s about strategic alignment. In a move that defied industry norms, OneSkin wasn’t actively seeking capital. Instead, Prelude Growth Partners approached the brand directly, driven by their conviction in OneSkin’s mission and market potential. The investment also allowed OneSkin to replace an early seed investor with a partner they believe is better aligned to support their next stage of growth.
“This strategic investment underscores Prelude Growth’s belief in the long-term potential of skin longevity as a category and in OneSkin’s leadership at…
the forefront of this movement,” the company shared in its announcement. The Science of Extending “Skinspan” Founded by a team of female PhD scientists, OneSkin brings a breakthrough philosophy to beauty and skincare: focusing on “skinspan,” the period during which skin remains healthy and functional.
Instead of targeting only the surface signs of aging, OneSkin’s research zeroes in on aging at the cellular level, particularly senescent cells.
These senescent cells are aging or dysfunctional cells that build up over time, contributing to inflammation, collagen degradation, and other biological factors connected to wrinkles, sagging, and dullness.
OneSkin’s proprietary peptide, OS-01, was developed to reduce the burden of these cells, ultimately aiming to make skin look and behave like younger skin…
Discussion
0 Comments
No comments yet
Start the conversation
Share your take on this story and help shape the discussion.
Sign in to join the discussion.